信邦製藥(002390.SZ):2024年度淨利潤預降58%-70%
格隆匯1月24日丨信邦製藥(002390.SZ)公佈2024年度業績預吿,2024年歸屬於上市公司股東的淨利潤盈利8,616.98萬元-12,063.78萬元,比上年同期下降70%-58%;扣除非經常性損益後的淨利潤盈利13,930.93萬元-18,753.18萬元,比上年同期下降48%-30%;基本每股收益盈利0.04元/股-0.06元/股。
公司醫藥流通板塊、醫療服務板塊營業收入下降,報吿期公司綜合毛利率下降;公司順應醫藥行業改革,推進全面預算管理,加強各項成本管控,實施精細化管理,合理統籌營運資金的使用,增加了經營性現金流,期間費用有所降低;非經常性損益事項增加。上述原因導致公司歸屬於上市公司股東的淨利潤較上年同期減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.